Determination of candesartan or olmesartan in hypertensive patient plasma using UPLC-MS/MS

Abstract

Candesartan and olmesartan are angiotensin II receptor blockers (ARBs) used for the treatment of hypertension and heart failure. Quantitation methods for candesartan and olmesartan were developed using ultra-high performance liquid chromatography-tandem mass spectrometry following protein precipitation. Candesartan was separated using 5 mM ammonium formate (A) and 100% acetonitrile (B) and olmesartan was separated using 2 mM ammonium formate with 0.1% formic acid (A) and 100% acetonitrile (B). Separation was performed using an isocratic method with a Thermo hypersil GOLD C18 column. Electrospray ionization was used for analyte ionization and detection of candesartan, olmesartan, and the internal standards by multiple reaction monitoring. Developed method showed excellent linearity ( r > 0.99) in the concentration range of 2–500 ng/mL for candesartan and 5–2,500 ng/mL for olmesartan. Accuracies were 86.70–108.8% for candesartan and 87.87–112.6% for olmesartan. These methods were able to successfully measure plasma candesartan or olmesartan concentrations in hypertensive patients. This study can be used for pharmacokinetic studies of candesartan or olmesartan in humans.

Clinical diagnosis of pheochromocytoma and paraganglioma‐induced secondary hypertension through UPLC‐MS/MS analysis of plasma catecholamines and their metabolites

“…Chen and coworkers reported that the UPLC‐MS/MS method is the gold standard for the diagnosis of conventional high‐throughput biological monoamines in catecholamine‐producing tumors 32 . In addition, a previous study demonstrated that the UPLC‐MS/MS method can be successfully used for the assessment of plasma candesartan and olmesartan levels in patients with hypertension 33 . Consistently, in the present study, we demonstrated that patients with high catecholamine levels exhibited more typical imaging manifestations, increased liquefactive necrosis in the tumor, and preoperative medication preparation.…”

Validated stability-indicating RP-HPLC method for simultaneous estimation of candesartan and pioglitazone in human plasma

“…(6) PPAR-gamma is a nuclear receptor activated by Pioglitazone (7)Treatment with any of several available Ang II receptor blockers (ARBs), agents that bind antagonistically to the Ang II, type I receptor (AT1R), resulted in renoprotection, according to clinical and basic research investigations. (8)(9)(10) This one ARB, Candesartan which is routinely taken to decrease blood pressure, has been unambiguously established to enhance renal function and ameliorate renal disease. (11,12).A review of the literature concluded that a few techniques, such as Ultra Performance Liquid Chromatography (13,14), High-Performance Liquid Chromatography (15,16), and Ultraviolet Spectroscopy (17,18), have been published for quantifying candesartan and pioglitazone bio analytically.…”